48 completed, 11 unknown, 7 terminated, 6 recruiting. 84 Phase 1, 20 Phase 2.
Follow Vaginal Diseases: new trials by email Literature Review of Vaginal Diseases trials Research Report on Vaginal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test New Investigational Drugs (LCFA-01and LC103) for Bacterial Vaginosis (BV) Treatment metronidazole (MTZ)+ LCFA-01 placebo + LC103 placebo, metronidazole (MTZ)+ LCFA-01 + LC103 placebo, metronidazole (MTZ)+ LC103 + LCFA-01 placebo - Bacterial Vaginosis | Phase 1 | Not yet recruiting | Massachusetts General Hospital | 280 | 2027-02-03 | 2026-10-15 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women GenSci142, Placebo GenSci142 - Bacterial Vaginosis | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 30 | 2025-12-01 | 2025-12-24 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma SCG142, Cyclophosphamide, Fludarabine - HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | SCG Cell Therapy Pte. Ltd. | 66 | 2024-10-01 | 2024-07-17 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis BNT331, Placebo - Bacterial Vaginosis | Phase 1 | Completed | BioNTech SE | 102 | 2024-07-01 | 2026-10-05 |
| Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers CanProFem-AK - Candidosis Vaginal | Phase 1 | Completed | Industrial Microbiology LLP | 20 | 2024-06-01 | 2024-08-02 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study Vaccine - Recurrent Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Active not recruiting | LimmaTech Biologics AG | 251 | 2023-12-06 | 2026-03-04 |
| HRYZ-T101 Injection for HPV18 Positive Solid Tumor HRYZ-T101 Injection, Fludarabine + Cyclophosphamide - Cervical Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | HRYZ Biotech Co. | 32 | 2023-11-01 | 2024-02-02 |
| Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest), Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin), Suppositoria for vaginal microflora recovery (Giynoflor) - Bacterial Vaginosis | Phase 1 | Active not recruiting | Danylo Halytsky Lviv National Medical University | 200 | 2023-09-01 | 2024-09-27 |
| SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas SCG142 TCR-T cells - Human Papillomavirus Associated Carcinomas, Cervical Cancer | Phase 1 | Recruiting | The Affiliated Hospital of Qingdao University | 18 | 2023-08-02 | 2024-08-09 |
| Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp Ibrexafungerp - Vulvovaginal Candidiasis, Candida Infection | Phase 1 | Completed | Scynexis, Inc. | 5 | 2023-07-12 | 2025-08-08 |
| HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell - Cervical Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Unknown | HRYZ Biotech Co. | 17 | 2023-03-21 | 2024-02-02 |
| Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women Experimental: Low dose LABTHERA-001 capsule, Experimental: Medium dose LABTHERA-001 capsule, Experimental: High dose LABTHERA-001 capsule - Bacterial Vaginosis, Vaginal Disease | Phase 1 | Unknown | AtoGen Co. Ltd | 24 | 2022-11-02 | 2023-03-09 |
| First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories, Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories - Colpomycosis, Bacterial Vaginosis | Phase 1 | Unknown | Protelight Pharmaceuticals Australia PTY LTD | 50 | 2022-08-01 | 2023-12-11 |
| Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV) Cervicovaginal secretions, Metronidazole gel, Screening tests - Bacterial Vaginosis | Phase 1 | Withdrawn | Johns Hopkins University | 2022-03-01 | 2021-11-03 | |
| Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis Conjugated Estrogens vaginal cream 0,625mg, platelet rich plasma - Atrophic Vaginitis, Postmenopausal Atrophic Vaginitis | Phase 1 | Unknown | Fayoum University | 100 | 2021-11-13 | 2023-05-01 |
Showing 20 of 84. Sign in to see all of them.
Uterine Cervical Neoplasms (38) · Vaginal Neoplasms (38) · Vulvar Neoplasms (25) · Vaginosis, Bacterial (23) · Endometrial Neoplasms (20) · Anus Neoplasms (16) · Carcinoma, Ovarian Epithelial (14) · Penile Neoplasms (14) · Fallopian Tube Neoplasms (13) · Urinary Bladder Neoplasms (11) · Candidiasis, Vulvovaginal (10) · Prostatic Neoplasms (10) · Carcinoma, Hepatocellular (9) · Colonic Neoplasms (9) · Neoplasms (9)
Female Urogenital Diseases and Pregnancy Complications (84) · Genital Diseases (84) · Urogenital Diseases (84) · Female Urogenital Diseases (83) · Genital Diseases, Female (83) · Neoplasms by Site (39) · Uterine Diseases (39) · Infections (38) · Urogenital Neoplasms (38) · Uterine Cervical Diseases (38) · Genital Neoplasms, Female (37) · Vulvar Diseases (35) · Uterine Neoplasms (34) · Vaginitis (34)
Metronidazole (6) · Radiotherapy (5) · Cyclophosphamide (4) · fludarabine (4) · Brachytherapy (3) · Capecitabine (2) · Cisplatin (2) · Control Groups (2) · Estriol (2) · Magnetic Resonance Spectroscopy (2) · Radiation (2) · Radiosurgery (2) · Topotecan (2) · Trastuzumab (2) · Vaccines (2)
National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (3) · Case Comprehensive Cancer Center (2) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · HRYZ Biotech Co. (2) · Regeneron Pharmaceuticals (2) · The University of Texas Medical Branch, Galveston (2) · University of Chicago (2) · Abramson Cancer Center at Penn Medicine (1) · Ain Shams University (1) · Alliance for Clinical Trials in Oncology (1) · Anthony Lembo (1) · AtoGen Co. Ltd (1) · Beijing Health Guard Biotechnology, Inc (1) · BioNTech SE (1)
United States (42) · China (9) · Canada (5) · Australia (3) · Belgium (3) · Egypt (2) · Germany (2) · Israel (2) · Spain (2) · United Kingdom (2) · Brazil (1) · France (1) · Japan (1) · Kazakhstan (1) · Kenya (1)
Jian Zhang, Doctor (2) · Lilie L Lin (2) · William P. Tew, MD (2) · Ahinoam Lev-Sagie (1) · Alan Bocking, MD, FRCSC (1) · Amy L Lightner (1) · Amy Lightner, MD (1) · Ann H Klopp (1) · Anthony Fyles, MD (1) · Anthony W. Tolcher, MD (1) · Ashwin Chatwani, MD (1) · Charles Erlichman, MD (1)
PMID 19949018, PMID 22002018, PMID 19238149, PMID 20068553, PMID 20179219, PMID 20347480, PMID 24718774, PMID 25427450, PMID 26223323, PMID 27093291, PMID 27412883, PMID 28363809, PMID 29697768, PMID 39836666, PMID 40273550, PMID 41291715
2023 (2), P30CA043703 (2), 2014 (1), P30CA016087 (1), P30CA016672 (1), U01CA062502 (1), U01CA076576 (1), U01CA076642 (1), UM1CA186644 (1)